CSF3 and breast cancer: Both the EORTC and ASCO guidelines present good evidence that prophylactic G-CSF decreases the incidence of dose reductions and delays, and advocate the use of primary prophylaxis to maintain the intended dose intensity of chemotherapy when survival benefits are expected, such as in patients with breast cancer or NHL.